Practical eminence and experience-based recommendations for use of tnf-α inhibitors in sarcoidosis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 31, Issue 2, 2014, Pages 91-107

  Drent, Marjolein ^a,b   Cremers, Johanna P ^a   Jansen, Tim L ^c   Baughman, Robert P ^d  

^a GELDERSE VALLEI HOSPITAL   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Adalimumab; Infliximab; Recommendations; Sarcoidosis; TNF inhibitors

Indexed keywords

ADALIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

BREAST FEEDING; CLINICAL PRACTICE; DELPHI STUDY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; LUNG SARCOIDOSIS; MAINTENANCE DRUG DOSE; NORTH AMERICA; PRIORITY JOURNAL; PULMONOLOGIST; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOLOGY; SARCOIDOSIS; TREATMENT DURATION; VIDEOCONFERENCING; ANTAGONISTS AND INHIBITORS; CONSENSUS; DRUG ADMINISTRATION; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PRACTICE GUIDELINE; TREATMENT OUTCOME;

CONSENSUS; DELPHI TECHNIQUE; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR TARGETED THERAPY; SARCOIDOSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84906053362     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and otherGranulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16 (2): 149-73.
2. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. Jama 2011; 305 (4): 391-9.
3. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis.Am J Respir Crit CareMed 2011; 183 (5): 573-81.
4. Baughman RP, Nunes H, Sweiss NJ, Lower EE. Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J 2013; 41 (6): 1424-38.
5. Korsten P, Mirsaeidi M, Sweiss NJ. Nonsteroidal therapy of sarcoidosis. Curr Opin Pulm Med 2013; 19 (5): 516-23.
6. Grutters JC, van den Bosch JM. Corticosteroid treatment in sarcoidosis. Eur Respir J 2006; 28 (3): 627-36.
7. Baughman RP. Pulmonary sarcoidosis. Clin Chest Med 2004; 25 (3): 521-30, vi.
8. Paramothayan S, Lasserson T. Treatments for pulmonary sarcoidosis. Respir Med 2008; 102 (1): 1-9.
9. Paramothayan S, Lasserson TJ, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Data base Syst Rev 2006; (3): CD003536.
10. Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide.Curr Opin PulmMed 2013; 19 (5): 545-61.
11. Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med 2010; 104 (5): 717-23.
12. Baughman RP,DrentM, KavuruM, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174 (7): 795-802.
13. Ziegenhagen MW, Rothe ME, Zissel G,Muller-Quernheim J. Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19 (3): 185-90.
14. Antoniu SA. Targeting the TNF-Alpha pathway in sarcoidosis. Expert Opin Ther Targets 2010; 14 (1): 21-9.
15. Loza MJ, Brodmerkel C, Du Bois RM, et al. Inflammatory profile and response to anti-Tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis. Clin Vaccine Immunol 2011; 18 (6): 931-9.
16. Aaltonen KJ, Virkki LM,Malmivaara A, Konttinen YT,Nordstrom DC, Blom M. Systematic review and meta-Analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012; 7 (1): e30275.
17. Osterman MT, Haynes K, Delzell E, et al. Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease. Clin Gastroenterol Hepatol 2013.
18. Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease.World J Gastroenterol 2012; 18 (35): 4823-54.
19. JudsonMA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31 (6): 1189-96.
20. Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (3): 201-8.
21. Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2013; 68 (5): 765-73.
22. Erckens RJ,Mostard RL,Wijnen PA, Schouten JS,DrentM. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2012; 250 (5): 713-20.
23. Liu Y,Wu EQ, Bensimon AG, et al. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. Adv Ther 2012; 29 (7): 620-34.
24. Rosenblum H, Amital H. Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev 2011; 10 (9): 563-8.
25. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-Analysis and Cochrane overview. Cochrane Database Syst Rev 2011; (2): CD008794.
26. De Meyrick J. The Delphi method and health research. Health Educ 2003; 103: 7-16.
27. Denmark VK, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert Rev Clin Immunol 2013; 9 (1): 77-92.
28. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2013.
29. Rubin DT, Panaccione R, Chao J, Robinson AM. A practical, evidence-based guide to the use of adalimumab in Crohn's disease. Curr Med Res Opin 2011; 27 (9): 1803-13.
30. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59 (6): 762-84.
31. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64 (5): 625-39.
32. Furst DE, Keystone EC, So AK, et al.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013; 72 Suppl 2: ii2-34.
33. D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of theWorld Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106 (2): 199-212; quiz 3.
34. Wijnen PA, Cremers JP, Nelemans PJ, et al. Association of the TNF-A G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur Respir J 2014; 43: 1730-9.
35. Hostettler KE, Studler U, Tamm M, Brutsche MH. Long-Term treatment with infliximab in patients with sarcoidosis. Respiration 2012; 83 (3): 218-24.
36. Orum M, Hilberg O, Krag S, Bendstrup E. Beneficial effect of infliximab on refractory sarcoidosis.DanMed J 2012; 59 (12): A4535.
37. Keijsers RG, Verzijlbergen JF, van Diepen DM, van den Bosch JM, Grutters JC. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25 (2): 143-9.
38. Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 2006; 100 (11): 2053-9.
39. Doty JD,Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005; 127 (3): 1064-71.
40. Milman N, Graudal N, Loft A, Mortensen J, Larsen J, Baslund B. Effect of the TNF-Alpha inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDGPET. Clin Respir J 2012; 6 (4): 238-47.
41. Banse C, Bisson-Vaivre A, Kozyreff-Meurice M, Vittecoq O, Goeb V.No impact of tumor necrosis-factor antagonists on the joint manifestations of sarcoidosis. Int J Gen Med 2013; 6: 605-11.
42. Baughman RP, Lower EE, Ingledue R, Kaufman AH.Management of ocular sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29 (1): 26-33.
43. Elfferich MD, Nelemans PJ, Ponds RW, De Vries J, Wijnen PA, Drent M. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-Alpha treatment. Respiration 2010; 80 (3): 212-9.
44. Baughman R.Tumor necrosis factor inhibition in treating sarcoidosis: the American experience. Rev Port de Pneumologia 2007; 8: S47-S50.
45. Goenka N, Venna N. Teaching NeuroImages: Sarcoidosis presenting as longitudinally extensive myelitis: Excellent response to infliximab. Neurology 2013; 81 (9): e61.
46. Vorselaars AD, Sjogren EV, van Moorsel CH, Grutters JC. Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy. Case Rep Pulmonol 2013; 2013: 308092.
47. Tu J, Chan J. Cutaneous sarcoidosis and infliximab: evidence for efficacy in refractory disease. Australas J Dermatol 2013.
48. O'Reilly MW, Sexton DJ, Dennedy MC, et al. Radiological remission and recovery of thirst appreciation after infliximab therapy in adipsic diabetes insipidus secondary to neurosarcoidosis. Qjm 2013.
49. Vorselaars AD, Keijsers RG, Grutters JC. Earlobe sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29 (1): 55-7.
50. Huffstutter JG, Huffstutter JE. Hypercalcemia from sarcoidosis successfully treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29 (1): 51-2.
51. Chintamaneni S, Patel AM, Pegram SB, Patel H, Roppelt H. Dramatic response to infliximab in refractory neurosarcoidosis. Ann Indian Acad Neurol 2010; 13 (3): 207-10.
52. Pereira J, Anderson NE, McAuley D, Bergin P, Kilfoyle D, Fink J. Medically refractory neurosarcoidosis treated with infliximab. Intern Med J 2011; 41 (4): 354-7.
53. Santos E, Shaunak S, Renowden S, Scolding NJ. Treatment of refractory neurosarcoidosis with Infliximab. J Neurol Neurosurg Psychiatry 2010; 81 (3): 241-6.
54. Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 2009; 72 (4): 337-40.
55. SodhiM, Pearson K,White ES, Culver DA. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med 2009; 103 (2): 268-73.
56. Barnabe C, McMeekin J, Howarth A, Martin L. Successful treatment of cardiac sarcoidosis with infliximab. J Rheumatol 2008; 35 (8): 1686-7.
57. Dolhun R, Sriram S. Neurosarcoidosis presenting as longitudinally extensive transverse myelitis. J Clin Neurosci 2009; 16 (4): 595-7.
58. Petropoulos IK, Vaudaux JD, Guex-Crosier Y. Anti-TNF-Alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital. Klin Monbl Augenheilkd 2008; 225 (5): 457-61.
59. Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 2005; 43 (1): 7-11.
60. Kumar G, Kang CA, Giannini C. Neurosarcoidosis presenting as a cerebellar mass. J Gen Intern Med 2007; 22 (9): 1373-6.
61. Toth C, Martin L, Morrish W, Coutts S, Parney I. Dramatic MRI improvement with refractory neurosarcoidosis treated with infliximab. Acta Neurol Scand 2007; 116 (4): 259-62.
62. Uthman I, Touma Z, Khoury M. Cardiac sarcoidosis responding to monotherapy with infliximab. Clin Rheumatol 2007; 26 (11): 2001-3.
63. Hoitsma E, Faber CG, van Santen-Hoeufft M, De Vries J, Reulen JP, Drent M. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (1): 73-7.
64. Salama B, Gicquel JJ, Lenoble P, Dighiero PL. Optic neuropathy in refractory neurosarcoidosis treated with TNF-Alpha antagonist. Can J Ophthalmol 2006; 41 (6): 766-8.
65. Benitez-del-Castillo JM,Martinez-de-la-Casa JM, Pato-Cour E, et al. Long-Term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye (Lond) 2005; 19 (8): 841-5.
66. Carter JD, Valeriano J, Vasey FB, Bognar B. Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med 2004; 117 (4): 277-9.
67. Sollberger M, Fluri F, Baumann T, et al. Successful treatment of steroid-refractory neurosarcoidosis with infliximab. J Neurol 2004; 251 (6): 760-1.
68. Katz JM, Bruno MK,Winterkorn JM, Nealon N. The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab. Arch Neurol 2003; 60 (3): 426-30.
69. Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest 2003; 124 (5): 2028-31.
70. Pettersen JA, Zochodne DW, Bell RB,Martin L,HillMD. Refractory neurosarcoidosis responding to infliximab. Neurology 2002; 59 (10): 1660-1.
71. Dragnev D, Barr D, Kulshrestha M, Shanmugalingam S. Sarcoid panuveitis associated with etanercept treatment, resolving with adalimumab. BMJ Case Rep 2013 [Epub ahead of print].
72. Kamphuis LS, Lam-TseWK, DikWA, et al. Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis. Am J Respir Crit Care Med 2011; 184 (10): 1214-6.
73. Patel SR. Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report. J Med Case Rep 2009; 3: 8573.
74. Hasni SA, Kunz D, Finzel K,Gruber BL.Osseous sarcoidosis treated with tumor necrosis factor-inhibitors: case report and review of the literature. Spine (Phila Pa 1976) 2010; 35 (18): E904-7.
75. Te HS, Campbell L, Chohan S. Infliximab therapy for hepatic and intestinal sarcoidosis. Gastroenterol Hepatol (N Y) 2007; 3 (6): 447-52.
76. Ahmed MM,Mubashir E, Dossabhoy NR. Isolated renal sarcoidosis: a rare presentation of a rare disease treated with infliximab. Clin Rheumatol 2007; 26 (8): 1346-9.
77. Thumfart J, Muller D, Rudolph B, Zimmering M, Querfeld U, Haffner D. Isolated sarcoid granulomatous interstitial nephritis responding to infliximab therapy. Am J Kidney Dis 2005; 45 (2): 411-4.
78. Hommes DW, Oldenburg B, van Bodegraven AA, et al. Guidelines for treatment with infliximab for Crohn's disease.Neth JMed 2006; 64 (7): 219-29.
79. Russell E, Luk F,Manocha S,Ho T,O'Connor C,Hussain H. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy. Semin Arthritis Rheum 2013; 43 (1): 119-24.
80. Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25 (2): 76-89.
81. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124 (1): 177-85.
82. Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005; 128 (2): 1062-47.
83. Osterman MT, Lichtenstein GR. Current and Future Anti-TNF Therapy for Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2007; 10 (3): 195-207.
84. Bozkurt B, Torre-Amione G,Warren MS, et al. Results of targeted anti-Tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001; 103 (8): 1044-7.
85. Chung ES, Packer M, Lo KH, Fasanmade AA,Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-Alpha, in patients with moderate-To-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107 (25): 3133-40.
86. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109 (13): 1594-602.
87. Sood A, Midha V. Symptomatic sinus bradycardia with infliximab. Indian J Gastroenterol 2004; 23 (3): 118-9.
88. Sote Y,Green S,Maddison P. Complete heart block after infliximab therapy. Rheumatology (Oxford) 2008; 47 (2): 227-8.
89. Vorselaars AD, Verwoerd A, van Moorsel CH, Keijsers RG, Rijkers GT, Grutters JC. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J 2013 [Epub ahead of print].
90. Dasilva V, Breuil V,Chevallier P, Euller-Ziegler L. Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFalpha blockade. Efficacy of rituximab, report of a single case. Joint Bone Spine 2010; 77 (1): 82-3.
91. de Vries HS, van Oijen MG, Driessen RJ, et al. Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Br J Clin Pharmacol 2011; 71 (1): 7-19.
92. Orlando A, Armuzzi A, Papi C, et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-Alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2011; 43 (1): 1-20.
93. Lower EE, Baughman RP, Kaufman AH. Rituximab for refractory granulomatous eye disease. Clin Ophthalmol 2012; 6: 1613-8.
94. Beccastrini E,Vannozzi L, Bacherini D, Squatrito D, Emmi L. Successful treatment of ocular sarcoidosis with rituximab. Ocul Immunol Inflamm 2013; 21 (3): 244-6.
95. Kavanaugh A, Smolen JS. The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials. Clin Exp Rheumatol 2013; 31 (4 Suppl 78): S19-21.
96. Tanaka Y, Hirata S, Saleem B, Emery P. Discontinuation of biologics in patients with rheumatoid arthritis. Clin Exp Rheumatol 2013; 31 (4 Suppl 78): S22-7.
97. Baughman RP, Drent M, Culver DA, et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29 (2): 90-8.
98. Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology 2009; 14 (4): 522-8.
99. van den Broek M, LemsWF, Allaart CF. Do we need guidelines to stop as well as to start biological therapies for rheumatoid arthritis? Clin Exp Rheumatol 2012; 30 (4 Suppl 73): S21-6.
100. Papa A, Mocci G, Bonizzi M, et al. Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol 2009; 104 (6): 1575-86.
101. Redelman-Sidi G, Sepkowitz KA. IFN-gamma release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med 2013; 188 (4): 422-31.
102. PouwMF, Krieckaert CL,NurmohamedMT, et al. Key findings towards optimising adalimumab treatment: the concentration effect curve. Ann Rheum Dis 2013; Epub ahead of print.